D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Journal ArticleDOI
From individualised treatment goals to personalised rehabilitation in osteoarthritis: a longitudinal prospective mapping study using the WHO international classification for functioning, disability and health
Sinisa Stefanac,Claudia Oppenauer,Michaela Zauner,Martina Durechova,Daffodil Dioso,Daniel Aletaha,Gerhard M. Hobusch,Reinhard Windhager,Tanja Stamm +8 more
TL;DR: In patients with osteoarthritis, the Goal Attainment Scale instrument can be used to measure health outcomes at different time points and its content may be linked to ICF providing a unified language and conceptual scientific basis.
Journal ArticleDOI
Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
Tom W J Huizinga,Ernest Choy,Amy Praestgaard,Hubert van Hoogstraten,Patrick LaFontaine,Patricia Guyot,Daniel Aletaha,Ulf Müller-Ladner,Yoshiya Tanaka,Jeffrey R. Curtis,Roy Fleischmann +10 more
TL;DR: In the absence of head-to-head clinical trials, the matching-adjusted indirect comparison (MAIC) and simulated treatment comparison (STC) as mentioned in this paper estimate the relative efficacy of sarilumab and upadacitinib in patients with RA who had an inadequate response to previous biologic DMARDs.
Journal ArticleDOI
Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study
Anselm Jorda,Felix Bergmann,Robin Ristl,Helga Radner,Daniela Sieghart,Daniel Aletaha,Markus Zeitlinger +6 more
TL;DR: In this paper , a secondary analysis of a prospective cohort study included 484 healthcare workers who received a booster vaccination with BNT162b2 and found no correlation between the severity of post-booster symptoms and anti-SARS-CoV-2 antibody levels at 28 days.
Journal ArticleDOI
OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions
Maya H Buch,Bernard Combe,José A. Gómez-Puerta,Roberto Caporali,Jacques-Eric Gottenberg,Vijay R. Rajendran,Pieter-Jan Stiers,Katrien Van Beneden,Daniel Aletaha,Gerd R Burmester,Rene Westhovens,Yoshiya Tanaka +11 more
TL;DR: Combe et al. as mentioned in this paper reported updated data on AEs of special interest (AESIs) and efficacy in these age groups. But they did not report the adverse events of AESIs.
Journal ArticleDOI
Ab0056 cytokine-directed cellular crosstalk imprints synovial pathotypes in rheumatoid arthritis
Maximilian Kugler,Mirjam Dellinger,Felix Kartnig,Lena Müller,Teresa Preglej,Leonhard X. Heinz,Elisabeth Simader,Lisa Göschl,Sandra Puchner,S. Weiss,J S Smole,German C. Steiner,Daniel Aletaha,H. Kiener,Anela Tosevska,Thomas Karonitsch,Michael Bonelli +16 more
TL;DR: In this article , the effect of cytokine-induced FLS on the development of CD4+ T cells was analyzed using RNA sequencing (RNA-seq) and quantified using high-content fluorescence microscopy combined with bioinformatic image analysis.